Comprehensive analysis of genomic alterations detected by next‑generation sequencing‑based tissue and circulating tumor DNA assays in Chinese patients with non‑small cell lung cancer

Yang,Hua; Zhang,Junjie; Zhang,Lemeng; Wen,Xiaoping; Luo,Yongzhong; Yao,Dingquan; Cheng,Tianli; Cheng,Huanqing; Wang,Huina; Lou,Feng; Guo,Jing; Liang,Xiayuan; Cao,Shanbo; Chen,Jianhua

doi:10.3892/ol.2019.10791

Comprehensive analysis of genomic alterations detected by next‑generation sequencing‑based tissue and circulating tumor DNA assays in Chinese patients with non‑small cell lung cancer

Authors:
- Hua Yang
- Junjie Zhang
- Lemeng Zhang
- Xiaoping Wen
- Yongzhong Luo
- Dingquan Yao
- Tianli Cheng
- Huanqing Cheng
- Huina Wang
- Feng Lou
- Jing Guo
- Xiayuan Liang
- Shanbo Cao
- Jianhua Chen
View Affiliations

Affiliations: Department of Thoracic Internal Medicine, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya Medical School of Central South University, Changsha, Hunan 410013, P.R. China, Department of Anesthesiology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China, Acornmed Biotechnology Co., Ltd., Beijing 100176, P.R. China
Published online on: September 3, 2019 https://doi.org/10.3892/ol.2019.10791
Pages: 4762-4770
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

While tumor genotyping is the standard treatment for patients with non‑small cell lung cancer (NSCLC), spatial and temporal tumor heterogeneity and insufficient specimens can lead to limitations in the use of tissue‑based sequencing. Circulating tumor DNA (ctDNA) fully encompasses tumor‑specific sequence alterations and offers an alternative to tissue sample biopsies. However, few studies have evaluated whether the frequency of multiple genomic alterations observed following ctDNA sequencing is similar to that observed following tissue sequencing in NSCLC. Therefore, in the present study, targeted next‑generation sequencing (NGS) was performed on tissue and plasma ctDNA samples in 99 patients with NSCLC. Overall, the frequencies of genetic alterations detected in ctDNA were positively correlated with those detected via tissue profiling (r=0.812; P=0.022). Genomic data revealed significant mutual exclusivity between alterations in epidermal growth factor receptor (EGFR) and tumor protein 53 (TP53; P=0.020), and between alterations in EGFR and KRAS (P=0.008), as well as potential mutual exclusivity between alterations in EGFR and Erb‑B2 receptor tyrosine kinase 2 (P=0.059). Furthermore, the EGFR mutant allele frequency (MAF) was positively correlated with the TP53 MAF in individual tumors (r=0.773; P=0.005), and there was a marked difference in the EGFR MAF between patients with and without the TP53 mutation (P=0.001). Levels of the tumor serum marker CA242 in patients with ctDNA‑detectable mutations were higher compared with those in patients without ctDNA‑detectable mutations. The data from the present study highlight the importance of tissue and plasma ctDNA screening by NGS to guide personalized therapy and promote the clinical management of patients with NSCLC.

View Figures

View References

1	Liu K, Chen HL, Wang S, Gu MM, Chen XM, Zhang SL, Yu KJ and You QS: High expression of RIOK2 and NOB1 predict human non-small cell lung cancer outcomes. Sci Rep. 6:286662016. View Article : Google Scholar : PubMed/NCBI
2	Yang J, Lin J, Liu T, Chen T, Pan S, Huang W and Li S: Analysis of lncRNA expression profiles in non-small cell lung cancers (NSCLC) and their clinical subtypes. Lung Cancer. 85:110–115. 2014. View Article : Google Scholar : PubMed/NCBI
3	Torr LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
4	Tursz T, Andre F, Lazar V, Lacroix L and Soria JC: Implications of personalized medicine-perspective from a cancer center. Nat Rev Clin Oncol. 8:177–183. 2011. View Article : Google Scholar : PubMed/NCBI
5	Swanton C and Govindan R: Clinical implications of genomic discoveries in lung cancer. N Engl J Med. 374:1864–1873. 2016. View Article : Google Scholar : PubMed/NCBI
6	Berge EM and Doebele RC: Targeted therapies in non-small cell lung cancer: Emerging oncogene targets following the success of epidermal growth factor receptor. Semin Oncol. 41:110–125. 2014. View Article : Google Scholar : PubMed/NCBI
7	Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, et al: The 2015 world health organization classification of lung tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 10:1243–1260. 2015. View Article : Google Scholar : PubMed/NCBI
8	Vargas AJ and Harris CC: Biomarker development in the precision medicine era: Lung cancer as a case study. Nat Rev Cancer. 16:525–537. 2016. View Article : Google Scholar : PubMed/NCBI
9	Tsao AS, Scagliotti GV, Bunn PA Jr, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, et al: Scientific advances in lung cancer 2015. J Thorac Oncol. 11:613–638. 2016. View Article : Google Scholar : PubMed/NCBI
10	Shyr D and Liu Q: Next generation sequencing in cancer research and clinical application. Biol Proced Online. 15:42013. View Article : Google Scholar : PubMed/NCBI
11	Gagan J and Van Allen EM: Next-generation sequencing to guide cancer therapy. Genome Med. 7:802015. View Article : Google Scholar : PubMed/NCBI
12	Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, et al: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 366:883–892. 2012. View Article : Google Scholar : PubMed/NCBI
13	Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, et al: Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 311:1998–2006. 2014. View Article : Google Scholar : PubMed/NCBI
14	Crowley E, Di Nicolantonio F, Loupakis F and Bardelli A: Liquid biopsy: Monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 10:472–484. 2013. View Article : Google Scholar : PubMed/NCBI
15	Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, et al: Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 6:224ra242014. View Article : Google Scholar : PubMed/NCBI
16	Hicks JK, Saller J, Wang E, Boyle T and Gray JE: Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results. Lung Cancer. 111:135–138. 2017. View Article : Google Scholar : PubMed/NCBI
17	Xu S, Lou F, Wu Y, Sun DQ, Zhang JB, Chen W, Ye H, Liu JH, Wei S, Zhao MY, et al: Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients. Cancer Lett. 370:324–331. 2016. View Article : Google Scholar : PubMed/NCBI
18	Pisapia P, Pepe F, Smeraglio R, Russo M, Rocco D, Sgariglia R, Nacchio M, De Luca C, Vigliar E, Bellevicine C, et al: Cell free DNA analysis by SiRe^® next generation sequencing panel in non small cell lung cancer patients: Focus on basal setting. J Thorac Dis. 9 (Suppl 13):S1383–S1390. 2017. View Article : Google Scholar : PubMed/NCBI
19	Mayo-de-Las-Casas C, Jordana-Ariza N, Garzón-Ibañez M, Balada-Bel A, Bertrán-Alamillo J, Viteri-Ramírez S, Reguart N, Muñoz-Quintana MA, Lianes-Barragan P, Camps C, et al: Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions. Ann Oncol. 28:2248–2255. 2017. View Article : Google Scholar : PubMed/NCBI
20	Chen K, Zhang J, Guan T, Yang F, Lou F, Chen W, Zhao M, Zhang J, Chen S and Wang J: Comparison of plasma to tissue DNA mutations in surgical patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 154:1123–1131.e2. 2017. View Article : Google Scholar : PubMed/NCBI
21	Kimura K and Koike A: Ultrafast SNP analysis using the Burrows-Wheeler transform of short-read data. Bioinformatics. 31:1577–1583. 2015. View Article : Google Scholar : PubMed/NCBI
22	McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M and DePristo MA: The genome analysis toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20:1297–1303. 2010. View Article : Google Scholar : PubMed/NCBI
23	Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, Gabriel S, Meyerson M, Lander ES and Getz G: Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 31:213–219. 2013. View Article : Google Scholar : PubMed/NCBI
24	Li J, Lupat R, Amarasinghe KC, Thompson ER, Doyle MA, Ryland GL, Tothill RW, Halgamuge SK, Campbell IG and Gorringe KL: CONTRA: Copy number analysis for targeted resequencing. Bioinformatics. 28:1307–1313. 2012. View Article : Google Scholar : PubMed/NCBI
25	Campbell JD, Alexandrov A, Kim J, Wala J, Berger AH, Pedamallu CS, Shukla SA, Guo G, Brooks AN, Murray BA, et al: Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet. 48:607–616. 2016. View Article : Google Scholar : PubMed/NCBI
26	Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R, Rosenthal R, et al: Tracking the evolution of non-small cell lung cancer. N Engl J Med. 376:2109–2121. 2017. View Article : Google Scholar : PubMed/NCBI
27	Thompson JC, Yee SS, Troxel AB, Savitch SL, Fan R, Balli D, Lieberman DB, Morrissette JD, Evans TL, Bauml J, et al: Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA. Clin Cancer Res. 22:5772–5782. 2016. View Article : Google Scholar : PubMed/NCBI
28	Nahar R, Zhai W, Zhang T, Takano A, Khng AJ, Lee YY, Liu X, Lim CH, Koh TPT, Aung ZW, et al: Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing. Nat Commun. 9:2162018. View Article : Google Scholar : PubMed/NCBI
29	VanderLaan PA, Rangachari D, Mockus SM, Spotlow V, Reddi HV, Malcolm J, Huberman MS, Joseph LJ, Kobayashi SS and Costa DB: Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. Lung Cancer. 106:17–21. 2017. View Article : Google Scholar : PubMed/NCBI
30	Molina-Vila MA, Bertran-Alamillo J, Gascó A, Mayo-de-las-Casas C, Sánchez-Ronco M, Pujantell-Pastor L, Bonanno L, Favaretto AG, Cardona AF, Vergnenègre A, et al: Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer. Clin Cancer Res. 20:4647–4659. 2014. View Article : Google Scholar : PubMed/NCBI
31	Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M, Haller A, Lothaire P, Meert AP, Noel S, et al: The role of RAS oncogene in survival of patients with lung cancer: A systematic review of the literature with meta-analysis. Br J Cancer. 92:131–139. 2005. View Article : Google Scholar : PubMed/NCBI
32	Rotow J and Bivona TG: Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer. 17:637–658. 2017. View Article : Google Scholar : PubMed/NCBI
33	Li X, Cai W, Yang G, Su C, Ren S, Zhao C, Hu R, Chen X, Gao G, Guo Z, et al: Comprehensive analysis of EGFR-mutant abundance and its effect on efficacy of EGFR TKIs in advanced NSCLC with EGFR mutations. J Thorac Oncol. 12:1388–1397. 2017. View Article : Google Scholar : PubMed/NCBI
34	Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, et al: Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: The lung cancer mutation consortium experience. J Thorac Oncol. 10:768–777. 2015. View Article : Google Scholar : PubMed/NCBI
35	Pujol JL, Cooper EH, Lehmann M, Purves DA, Dan-Aouta M, Midander J, Godard P and Michel FB: Clinical evaluation of serum tumor marker CA 242 in non-small cell lung cancer. Br J Cancer. 67:1423–1429. 1993. View Article : Google Scholar : PubMed/NCBI